Therapeutic Response Statement (Sensitivity)

This therapeutic response statement Supports the relationship that EGFR activating variants status confers therapeutic sensitivity to Erlotinib in patients with Non-Small Cell Lung Cancer.

The Republic of Ireland's Health Service Executive (HSE) has approved erlotinib for reimbursement as a treatment option for switch maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating mutations and stable disease after first-line chemotherapy.

This statement is based on a regulatory approval from the Health Service Executive:

Switch maintenance treatment in patients with locally advanced or metastatic NSCLC with EGFR activating mutations and stable disease after first-line chemotherapy

Citation

Erlotinib Therapy, 2021, version number 5, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6938/219_V5_Erlotinib_monotherapy.pdf

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2016-03-25	Health Service Executive	Indication approved for reimbursement.